# Re‐evaluation of neotame (E 961) as food additive

**Authors:** Laurence Castle, Monica Andreassen, Gabriele Aquilina, Maria Lourdes Bastos, Polly Boon, Biagio Fallico, Reginald FitzGerald, Maria Jose Frutos Fernandez, Bettina Grasl‐Kraupp, Ursula Gundert‐Remy, Rainer Gürtler, Eric Houdeau, Marcin Kurek, Henriqueta Louro, Patricia Morales, Sabina Passamonti, Monika Batke, Ellen Bruzell, James Chipman, Riccardo Crebelli, Cristina Fortes, Peter Fürst, Eric Gaffet, Cheyns Karlien, Thorhallur Halldorsson, Jean‐Charles Leblanc, Oliver Lindtner, Katrin Loeschner, Jan Mast, Manuela Mirat, Alicja Mortensen, Anna Undas, Matthew Wright, Stefania Barmaz, Consuelo Civitella, Jose Cortiñas Abrahantes, Pauline Le Gall, Elena Mazzoli, Agnieszka Mech, Josef Daniel Rasinger, Ana Rincon, Francesca Riolo, Camilla Smeraldi, Alexandra Tard, Panagiota Zakidou, Federica Lodi

PMC · DOI: 10.2903/j.efsa.2025.9480 · 2025-07-04

## TL;DR

The safety of neotame, a food additive, was re-evaluated, and it was found to be safe at current usage levels.

## Contribution

The study re-evaluates neotame's safety and updates the acceptable daily intake based on new assessments.

## Key findings

- Neotame is rapidly absorbed and metabolized, with no significant genotoxicity concerns.
- An acceptable daily intake of 10 mg/kg body weight per day was established, replacing the previous 2 mg/kg.
- Dietary exposure estimates for neotame do not exceed the new ADI for all population groups.

## Abstract

The present opinion deals with the re‐evaluation of neotame (E 961) as a food additive. Neotame is the chemically manufactured compound N‐[N‐(3,3‐dimethylbutyl)‐l‐α‐aspartyl]‐l‐phenylalanine 1‐methyl ester. The main impurity of neotame (E 961) is also a degradation product (de‐esterified form), N‐[N‐(3,3‐dimethylbutyl)‐l‐α‐aspartyl]‐l‐phenylalanine (NC‐00751) and the primary metabolite. No new data were received following the call for biological and toxicological data. A summary of the toxicological studies available in the EFSA opinion of 2007 is presented and studies gathered from the literature are summarised. Neotame is rapidly absorbed and pre‐systemically metabolised, systemic intact neotame is likely to be excreted in the urine with its metabolites. The potential aneugenic effects at the site of contact are not expected to occur; overall, there is no concern for genotoxicity of neotame (E 961) at the maximum permitted levels or reported use levels. A review of the other endpoints from the already available toxicological database did not indicate an adverse effect for neotame at the highest doses tested. The Panel established an acceptable daily intake (ADI) of 10 mg/kg bw per day for neotame based on the no observed adverse effect level (NOAEL) of 1000 mg/kg bw per day from a 52‐week chronic and 104‐week carcinogenicity studies in rats. This ADI replaces the ADI of 2 mg/kg bw per day established by EFSA in 2007. The resulting exposure to methanol and its metabolite formaldehyde from the use of neotame at the ADI of 10 mg/kg bw per day does not raise a concern. The dietary exposure estimates of neotame (E 961) for the different population groups of all exposure scenarios did not exceed the ADI. The Panel concluded that there is no safety concern for neotame (E 961) at the currently permitted and reported uses and use levels. The Panel recommended the European Commission to consider revising the EU specifications of neotame (E 961).

## Linked entities

- **Chemicals:** neotame (PubChem CID 9810996), methanol (PubChem CID 887), formaldehyde (PubChem CID 712)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Diseases:** carcinogenicity (MESH:D011230)
- **Chemicals:** formaldehyde (MESH:D005557), methanol (MESH:D000432), N-[N-(3,3-dimethylbutyl)-l-alpha-aspartyl]-l-phenylalanine 1-methyl ester (MESH:C404525), N-[N-(3,3-dimethylbutyl)-l-alpha-aspartyl]-l-phenylalanine (-)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116]

## Figures

31 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12231243/full.md

---
Source: https://tomesphere.com/paper/PMC12231243